Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Vistide er større end risiciene ved behandling af CMV- retinitis hos patienter med aids og uden nyresygdom.
The Committee for Medicinal Products for Human Use (CHMP) decided that Vistide’ s benefits are greater than its risks for the treatment of CMV retinitis in patients with AIDS and without kidney disease.